Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Extended Use of rhPTH(1-84) in Hypoparathyroidism
NCT02910466Phase 4Completed
- Sponsor
- Takeda
- Start
- Oct 2016
- Primary completion
- Dec 2019
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label trial of parathyroid hormone 1-84 in hypoparathyroidism, sponsored by Takeda. Primary endpoint: Albumin-corrected Serum Calcium. Started Oct 2016; status: completed.
02
Drugs
parathyroid hormone 1-84
03
Conditions
hypoparathyroidism
Beyond the preview
Go deeper on NCT02910466.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02910466.